Evidence map›Paper›PMID 37774733›Full record

ArticleThe Lancet. Child & adolescent health2023

Paediatric acute hepatitis of unknown aetiology: a national investigation and adenoviraemia case-control study in the UK.

Sema Mandal, Ruth Simmons, Georgina Ireland, Andre Charlett, Monica Desai, Laura Coughlan, Annabel Powell, David Leeman, Christopher Williams, Claire Neill and 46 more

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in The Lancet. Child & adolescent health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Investigation of an outbreak of novel hepatitis of unknown aetiology in children and adolescents, Ireland, 2021 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

56 authors at 11 institutions in 1 country.

Sema MandalUK Health Security Agency, London, UK. Electronic address: Sema.Mandal@ukhsa.gov.uk.
Ruth SimmonsUK Health Security Agency, London, UK.
Georgina IrelandUK Health Security Agency, London, UK.
Andre CharlettUK Health Security Agency, London, UK.
Monica DesaiUK Health Security Agency, London, UK.
Laura CoughlanUK Health Security Agency, London, UK.
Annabel PowellUK Health Security Agency, London, UK.
David LeemanUK Health Security Agency, London, UK; UK Field Epidemiology Training Programme, UK Health Security Agency, London, UK.
Christopher WilliamsPublic Health Wales, Cardiff, UK.
Claire NeillPublic Health Agency, Belfast, UK.
Maureen C O'LearyPublic Health Scotland, Glasgow, UK.
Clare SawyerPublic Health Wales, Cardiff, UK.
Frances RowleyUK Field Epidemiology Training Programme, UK Health Security Agency, Cardiff, UK; Public Health Wales, Cardiff, UK.
Caroline HarrisPublic Health Wales, Cardiff, UK.
Catherine HoulihanUK Health Security Agency, London, UK; University College London, UK.
Claire GordonUK Health Security Agency, London, UK.
Tommy RamplingUK Health Security Agency, London, UK.
Helen CallabyUK Health Security Agency, London, UK; Medical Sciences, University of Aberdeen, Aberdeen, UK.
Katja HoschlerUK Health Security Agency, London, UK.
Jade CogdaleUK Health Security Agency, London, UK.
Erik RenzUK Health Security Agency, London, UK.
Praveen SebastianpilliUK Health Security Agency, London, UK.
Catherine ThompsonUK Health Security Agency, London, UK.
Tiina TaltsUK Health Security Agency, London, UK.
Cristina CelmaUK Health Security Agency, London, UK.
Emma A DaviesManchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, UK.
Shazaad AhmadPublic Health Scotland, Glasgow, UK; Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, UK.
Nicholas MachinManchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, UK.
Laura GiffordPublic Health Wales, Cardiff, UK.
Catherine MoorePublic Health Wales, Cardiff, UK.
Elizabeth M DicksonPublic Health Scotland, Glasgow, UK.
Titus H DivalaPublic Health Scotland, Glasgow, UK.
David HendersonPublic Health Scotland, Glasgow, UK.
Kathy LiBelfast Health and Social Care Trust, Belfast, UK.
Philip BroadbentPublic Health Scotland, Glasgow, UK.
Ines Ushiro-LumbUK Health Security Agency, London, UK; NHS Blood and Transplant, London, UK.
Clare HumphreysUK Health Security Agency, London, UK.
Tassos GrammatikopoulosKing's College Hospital NHS Foundation Trust, London, UK.
Jane HartleyBirmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
Chayarani KelgeriBirmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
Sanjay RajwalLeeds Teaching Hospitals NHS Trust, Leeds, UK.
Ifeanyichukwu OkikeDerbyshire Healthcare NHS Foundation Trust, Derby, UK.
Deirdre A KellyBirmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
Malcolm GuiverManchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, UK.
Ray BorrowUK Health Security Agency, London, UK; Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, UK.
Renu BindraUK Health Security Agency, London, UK.
Alicia DemirjianUK Health Security Agency, London, UK; Evelina Children's Hospital, London, UK; King's College London, London, UK.
Kevin E BrownUK Health Security Agency, London, UK.
Shamez N LadhaniUK Health Security Agency, London, UK.
Mary E RamsayUK Health Security Agency, London, UK.
Declan T BradleyPublic Health Agency, Belfast, UK.
Ardiana GjiniPublic Health Wales, Cardiff, UK.
Kirsty RoyPublic Health Scotland, Glasgow, UK.
Meera ChandUK Health Security Agency, London, UK.
Maria ZambonUK Health Security Agency, London, UK.
Conall H WatsonUK Health Security Agency, London, UK.
UK Health Security AgencyPublic Health Scotland · GBPublic Health Wales · GBManchester Royal Infirmary · GBBirmingham Women’s and Children’s NHS Foundation Trust · GBPublic Health Agency · GBBelfast Health and Social Care Trust · GBKing's College Hospital NHS Foundation Trust · GBKing's College London · GBLeeds Teaching Hospitals NHS Trust · GBNHS Blood and Transplant · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn increase in acute severe hepatitis of unknown aetiology in previously healthy children in the UK in March, 2022, triggered global case-finding. We aimed to describe UK epidemiological investigations of cases and their possible causes.

methodsWe actively surveilled unexplained paediatric acute hepatitis (transaminase >500 international units per litre) in children younger than 16 years presenting since Jan 1, 2022, through notifications from paediatricians, microbiologists, and paediatric liver units; we collected demographic, clinical, and exposure information. Then, we did a case-control study to investigate the association between adenoviraemia and other viruses and case-status using multivariable Firth penalised logistic regression. Cases aged 1-10 years and tested for adenovirus were included and compared with controls (ie, children admitted to hospital with an acute non-hepatitis illness who had residual blood samples collected between Jan 1 and May 28, 2022, and without known laboratory-confirmed diagnosis or previous adenovirus testing). Controls were frequency-matched on sex, age band, sample months, and nation or supra-region with randomised selection. We explored temporal associations between frequency of circulating viruses identified through routine laboratory pathogen surveillance and occurrence of cases by linear regression. SARS-CoV-2 seropositivity of cases was examined against residual serum from age-matched clinical comparison groups.

findingsBetween Jan 1 and July 4, 2022, 274 cases were identified (median age 3 years [IQR 2-5]). 131 (48%) participants were male, 142 (52%) were female, and one (<1%) participant had sex data unknown. Jaundice (195 [83%] of 235) and gastrointestinal symptoms (202 [91%] of 222) were common. 15 (5%) children required liver transplantation and none died. Adenovirus was detected in 172 (68%) of 252 participants tested, regardless of sample type; 137 (63%) of 218 samples were positive for adenovirus in the blood. For cases that were successfully genotyped, 58 (81%) of 72 had Ad41F, and 57 were identified as positive via blood samples (six of these were among participants who had undergone a transplant). In the case-control analysis, adenoviraemia was associated with hepatitis case-status (adjusted OR 37·4 [95% CI 15·5-90·3]). Increases in the detection of adenovirus from faecal samples, but not other infectious agents, in routine laboratory pathogen surveillance correlated with hepatitis cases 4 weeks later, which independently suggested an association (β 0·06 [95% CI 0·02-0·11]). No association was identified for SARS-CoV-2 antibody seropositivity.

interpretationWe observed an association between adenovirus 41F viraemia and paediatric acute hepatitis. These results can inform diagnostic testing recommendations, clinical management, and exploratory in vitro or clinical studies of paediatric acute hepatitis of unknown aetiology. The role of potential co-factors, including other viruses and host susceptibility, requires further investigation.

fundingNone.

Indexed as

COVID-19HepatitisAcute DiseaseCase-Control StudiesChild, PreschoolFemaleHumansMaleSARS-CoV-2United Kingdom

Identifiers

PMID37774733
OpenAlexW4387038198

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.